@entity955 affects approximately 5 million @entity1 in the United States. The rate of @entity64 in adults with @entity955 depending on their risk factors varies between 1-20% annually. Anticoagulation with @entity2067 antagonists such as @entity1229 has been the mainstay therapy but it is cumbersome and requires close follow-up. Since 2010, three new oral anticoagulants have received Food and Drug Administration approval for @entity64 prevention in @entity955 . This review summarizes data from three landmark trials: RE-LY, ROCKET-AF, and ARISTOTLE. In addition, issues relating to cost, reversal, drug interactions, and perioperative discontinuation are discussed. Compared to @entity1229 , @entity3926 150mg twice daily lowered the primary outcome of @entity64 /systemic @entity887 by 34% (number needed to treat/yr 169) and had similar incidence of @entity548 . Rivaroxaban demonstrated non inferiority compared to the @entity1229 group for the primary outcome of @entity64 and systemic @entity887 and @entity548 . @entity5424 showed a relative risk reduction for the primary outcome of 21% (number needed to treat300), and lowered @entity548 down by 31% (number needed to treat/yr 104). @entity5424 also showed a mortality benefit compared to @entity1229 (3.52 vs. 3.94%/year, p 0.047). All 3 oral anticoagulants lowered rates of @entity932 . The use of @entity3925 and @entity5424 has been projected to reduce medical costs when compared to @entity1229 , and @entity3926 is projected to have similar costs. All the 3 oral anticoagulants have robust randomized controlled trials supporting their comparability to @entity1229 therapy for @entity64 prevention in non @entity955 , with @entity5424 showing superiority in incidence of @entity64 , @entity548 , and mortality.

Oral Anticoagulation in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage'] @entity548 :: ('MESH:D006470', 'Disease') :: ['major bleeding'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['Dabigatran'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['Rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['Apixaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'Atrial fibrillation', 'valvular atrial fibrillation'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['Warfarin', 'warfarin']
@entity955 :: (MESH:D001281,Disease) :: ['Atrial Fibrillation']
